HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Almay

This article was originally published in The Rose Sheet

Executive Summary

Revlon appoints Arnell Group to oversee creative and media planning aspects of advertising for the brand, firm announces May 9. Omnicom Group subsidiary also will "act as a strategic partner for other aspects of Almay's marketing plan including promotional, interactive and retailer programs," Revlon notes, adding the agency is "renowned for integrating global brand platforms with holistic marketing strategies." Company launched an ad campaign featuring Elaine Irwin-Mellencamp last year to revitalize the Almay brand (1"The Rose Sheet" Feb. 23, 2004, p. 7)...

You may also be interested in...



Revlon Business Initiatives To Expand Operating Margins To 14%

Revlon is entering a new business phase where top and bottom line initiatives are expected to improve the cosmetic marketer's operating income margins from 4% in 2003 to appoximately 14% in the next three to five years, President and CEO Jack Stahl said during an analyst meeting in New York City Feb. 18

Metsera Launches As New Obesity Contender Flush With $290m

Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture. 

Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables

Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS013039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel